Why is Valneva stock surging today?

Valneva's stock soared 15.6% to €2.837 today following the European Medicines Agency's validation of its Marketing Authorization Application for a Lyme disease vaccine. This marks the beginning of a formal regulatory assessment that could result in Europe's first approved Lyme disease vaccine. The EMA validation was based on Phase 3 VALOR trial data showing the vaccine's efficacy in preventing Lyme disease in individuals aged five and older, with the vaccine reported as safe and well-tolerated.

The approval came just a day after Valneva's shares dropped following the release of its first-half 2026 financial results, which showed a net loss of €63.3 million, more than triple the €20.8 million loss from the same period a year earlier. The decline was due to lower gross margins, reduced travel vaccine volumes, and one-off charges related to contract terminations and inventory write-offs.

Despite the financial setback, management maintained its full-year 2026 product sales guidance of €135–€150 million and highlighted a strong cash position of €121.5 million, which boosted confidence in the company's short-term liquidity. The broader market remained largely neutral, with U.S. indices essentially flat and no major macro catalysts influencing sentiment.

Valneva's Lyme disease program, developed in partnership with Pfizer, remains a key asset in the vaccine and specialty biotech space, with regulatory decisions expected within the next twelve months.